Psychedelics & Cannabis

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

Answer a quick question on psychedelics!

Answer a quick question about psychedelics!

Answer a quick question on psychedelics!

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

Answer a quick question on psychedelics!

Learn more about the potential of MDMA-assisted psychotherapy.

Answer a quick question on psychedelics!

Answer a quick question on psychedelics!

Learning to use a psychedelic agent can be challenging when the protocols are not defined. Here’s how a psychiatrist got started.

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.

Here are highlights from the first day of this year’s APA Annual Meeting.

What are the connections between cannabis use and the onset of psychotic disorders?

Use this protocol, presented at the 2024 APA Annual Meeting, in patients with cannabis use disorder to bolster likelihood of cannabis cessation or reduction in use.

The proposed change acknowledges the medical applications of marijuana.

A look at the distinction between qualifying conditions and FDA-approved indications for medical marijuana use.

A psychiatrist explores ketamine-assisted psychotherapy in this ongoing series.

Here are highlights from the week in Psychiatric Times.

Psychedelics: it is time to integrate this treatment option into clinical care while holding fast to the principles of medical ethics.

Study results suggest the potential for a scalable, single-dose treatment approach.

Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.